| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6559305 | PFIZER | Linezolid—crystal form II |
Jan, 2021
(3 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5688792 | PFIZER | Substituted oxazine and thiazine oxazolidinone antimicrobials |
Nov, 2014
(9 years ago) | |
|
US5688792 (Pediatric) | PFIZER | Substituted oxazine and thiazine oxazolidinone antimicrobials |
May, 2015
(8 years ago) | |
| US6559305 | PFIZER | Linezolid—crystal form II |
Jan, 2021
(3 years ago) | |
| US6514529 | PFIZER | Oxazolidinone tablet formulation |
Mar, 2021
(3 years ago) | |
|
US6559305 (Pediatric) | PFIZER | Linezolid—crystal form II |
Jul, 2021
(2 years ago) | |
|
US6514529 (Pediatric) | PFIZER | Oxazolidinone tablet formulation |
Sep, 2021
(2 years ago) | |
Zyvox is owned by Pfizer.
Zyvox contains Linezolid.
Zyvox has a total of 7 drug patents out of which 7 drug patents have expired.
Expired drug patents of Zyvox are:
- US5688792
- US5688792*PED
- US6559305
- US6514529
- US6559305*PED
- US6514529*PED
- US6559305
Zyvox was authorised for market use on 18 April, 2000.
Zyvox is available in tablet;oral, for suspension;oral, solution;intravenous dosage forms.
Zyvox can be used as treatment of microbial infections.
The generics of Zyvox are possible to be released after 15 September, 2021.
Drugs and Companies using LINEZOLID ingredient
Market Authorisation Date: 18 April, 2000
Treatment: Treatment of microbial infections
Dosage: SOLUTION;INTRAVENOUS; FOR SUSPENSION;ORAL; TABLET;ORAL
ZYVOX family patents
